Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC

May 29th 2025

Panelists discuss how the diagnostic workup for unresectable stage III non–small cell lung cancer (NSCLC) requires comprehensive staging including imaging studies (PET-CT, brain MRI), tissue sampling through bronchoscopy or endobronchial ultrasound (EBUS), molecular and biomarker testing, and multidisciplinary evaluation to guide optimal treatment planning.

FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC

May 28th 2025

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer

May 28th 2025

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

Early Insights from ASCO 2025: Press Briefing Highlights with Clinical Impact

May 26th 2025

A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.

Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

May 23rd 2025

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.

The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

May 23rd 2025

Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.

Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

May 23rd 2025

Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC

May 22nd 2025

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

Health Canada Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

May 22nd 2025

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

FDA Grants Breakthrough Device Designation to EnVisio X1 for Minimally Invasive Surgery in Cancer Care

May 22nd 2025

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

Utilizing pCR, MPR, and Other Clinical Indicators to Guide Adjuvant Treatment Decisions in Early-Stage NSCLC

May 21st 2025

Panelists discuss how to treat patients who do not achieve a pathological complete response or major pathological response after neoadjuvant chemoimmunotherapy, considering options such as adjuvant therapy, close surveillance, or clinical trial enrollment based on individual risk factors and disease characteristics.

Leveraging MRD Testing to Guide Treatment Decisions in Early-Stage Resectable NSCLC

May 21st 2025

Panelists discuss how circulating tumor DNA could serve as a potential marker for minimal residual disease (MRD) in this setting, offering a noninvasive and sensitive method for monitoring treatment response and detecting relapse.

FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL-1310 in ES-SCLC

May 19th 2025

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 5/11

May 17th 2025

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

May 17th 2025

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC

May 16th 2025

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including MET-targeted approaches or chemotherapy combinations.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

May 15th 2025

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

May 15th 2025

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.